Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)
NIH to study Pfizer's Paxlovid in long Covid as demand — and infections — continue to fall
Pfizer’s Paxlovid will become the first treatment studied by the NIH for long Covid, the agency said Thursday.
The drug will be evaluated as part …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
